In reading the latest paper published by Dr. Patte
Post# of 154675
(Total Views: 1095)
Posted On: 11/22/2020 8:24:11 AM
In reading the latest paper published by Dr. Patterson and others at IncellDx, Cytek Biosciences, Qognit and Celsee we get a confirmation on the huge potential benefits of Vyrologix on the Oncology arena:
Dr. Patterson et-al also found that the expression of the checkpoint markers on CD103+, CD4+ T cells correlated with CTCs.
CTC’s, of course correlate to metastasis, the main cause of deaths in cancer.
Two points here: Vyrologix will be effective in treating some (if not all) Oncology indications (a humongous market) and the CTC’s count reductions that were observed in the first patients dosed with the drug have, yet another, depiction of moa (as if we needed it).
In any case, Dr. Patterson’s studies do continue to support the use of Vyrologix in “all CCR5” of which there is a myriad of indications.
We are sitting pretty here as sooner or latter the next Humira will hit the market, I just wished Cytodyn had a one-man research department. And if Father Christmas, after ascertaining that I have been a good boy throughout the year, would give me a gift I know who that person would be.
We at CYDY should be watching closely the L.H. results obtained already by Dr. Patterson et-al with their patients to fine-tune the protocol so we don't go the same route as with M/M (CD10) trial.
Quote:
The plot shows expression of CCR5 on Treg (CD4, CD25+ and CD127-). All lung cancer samples with CTCs demonstrated that the CD4+, CD103+ cells expressed FoxP3 and these cells also expressed CCR5, a chemokine receptor involved in chemotaxis of immune cells in response to CCL5.
Dr. Patterson et-al also found that the expression of the checkpoint markers on CD103+, CD4+ T cells correlated with CTCs.
CTC’s, of course correlate to metastasis, the main cause of deaths in cancer.
Two points here: Vyrologix will be effective in treating some (if not all) Oncology indications (a humongous market) and the CTC’s count reductions that were observed in the first patients dosed with the drug have, yet another, depiction of moa (as if we needed it).
In any case, Dr. Patterson’s studies do continue to support the use of Vyrologix in “all CCR5” of which there is a myriad of indications.
We are sitting pretty here as sooner or latter the next Humira will hit the market, I just wished Cytodyn had a one-man research department. And if Father Christmas, after ascertaining that I have been a good boy throughout the year, would give me a gift I know who that person would be.
We at CYDY should be watching closely the L.H. results obtained already by Dr. Patterson et-al with their patients to fine-tune the protocol so we don't go the same route as with M/M (CD10) trial.
(13)
(0)